OTCMKTS:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis $11.81 +0.47 (+4.14%) As of 02:39 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsShort Interest About LogicBio Therapeutics Stock (OTCMKTS:LOGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LogicBio Therapeutics alerts:Sign Up Key Stats Today's Range$10.93▼$11.9350-Day Range$8.60▼$11.5552-Week Range$7.05▼$11.93Volume48,075 shsAverage Volume139,712 shsMarket Capitalization$540.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Read More LogicBio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreLOGC MarketRank™: LogicBio Therapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for LogicBio Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -15.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -15.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LogicBio Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.96% of the float of LogicBio Therapeutics has been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 3.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LogicBio Therapeutics has recently increased by 1.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for LogicBio Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for LOGC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LogicBio Therapeutics' insider trading history. Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LOGC Stock News HeadlinesContextLogic Holdings Inc. Publishes Q&A Following Second Quarter 2026 ResultsAugust 21 at 8:00 AM | globenewswire.comContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comSilicon Valley Insider: "Forget AI Stocks"A 25-year Silicon Valley veteran who recommended Nvidia before its 32,000 percent run says the next wave of AI gains wont come from Nvidia, Tesla, or SpaceX. He points to a detail buried on page 37 of the SpaceX IPO filing, tied to Elon Musks plans for 1 million AI satellites, 1 billion humanoid robots, and 200 billion AI chips a year. He says one overlooked sector could benefit most from this spending, and has identified a company trading under $1 that may factor into Musks supply chain.August 24 at 1:00 AM | Brownstone Research (Ad)ContextLogic to Acquire gChem for $850 MillionAugust 5, 2026 | globenewswire.comContextLogic Appoints Seth Siegel as Senior AdvisorJuly 13, 2026 | globenewswire.comContextLogic Holdings Inc. Announces Scott Stewart as Chief Financial Officer & Chief Operating OfficerJune 1, 2026 | globenewswire.comContextLogic Holdings Inc. Publishes Q&A Following First Quarter 2026 ResultsMay 22, 2026 | globenewswire.comContextLogic Holdings Inc. Reports First-Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comSee More Headlines LOGC Stock Analysis - Frequently Asked Questions How have LOGC shares performed this year? LogicBio Therapeutics' stock was trading at $7.58 at the beginning of 2026. Since then, LOGC stock has increased by 53.6% and is now trading at $11.64. How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.10. The firm had revenue of $33.60 million for the quarter, compared to analysts' expectations of $33.60 million. How do I buy shares of LogicBio Therapeutics? Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Compass Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings8/13/2026Today8/24/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:LOGC CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year Founded2014Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29 million Net MarginsN/A Pretax Margin-93.64% Return on Equity-1.21% Return on Assets-0.89% Debt Debt-to-Equity Ratio0.29 Current Ratio1.87 Quick Ratio1.24 Sales & Book Value Annual Sales$43 million Price / Sales12.56 Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / Book2.39Miscellaneous Outstanding Shares45,730,000Free Float26,309,000Market Cap$540.07 million OptionableNo Data Beta2.02 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:LOGC) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then,...Porter & Company | Sponsored"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredGet this “Fed ticker” before September 16Barron's ranked Larry Benedict's former hedge fund among the top 1% in the world. He went 20 straight years wi...Brownstone Research | SponsoredIn 2022, every resident of this state received $3,284Since 1982, Alaska has paid every resident an annual check from its oil wealth, $3,284 in 2022 alone, funded e...Freedom Financial | Sponsored$2 an acre. They paid $412.The federal government rents desert land at $2 an acre. Recent bids hit $412 an acre, 206 times the asking pri...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
